| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FAM46C |
| Uniprot No | Q5VWP2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-391aa |
| 氨基酸序列 | MAEESSCTRDCMSFSVLNWDQVSRLHEVLTEVVPIHGRGNFPTLEITLKDIVQTVRSRLEEAGIKVHDVRLNGSAAGHVLVKDNGLGCKDLDLIFHVALPTEAEFQLVRDVVLCSLLNFLPEGVNKLKISPVTLKEAYVQKLVKVCTDTDRWSLISLSNKNGKNVELKFVDSIRRQFEFSVDSFQIILDSLLFFYDCSNNPISEHFHPTVIGESMYGDFEEAFDHLQNRLIATKNPEEIRGGGLLKYSNLLVRDFRPTDQEEIKTLERYMCSRFFIDFPDILEQQRKLETYLQNHFAEEERSKYDYLMILRRVVNESTVCLMGHERRQTLNLISLLALRVLAEQNIIPSATNVTCYYQPAPYVSDGNFSNYYVAHPPVTYSQPYPTWLPCN |
| 预测分子量 | 46.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FAM46C重组蛋白的参考文献示例(内容为示例性概括，非真实文献)：
---
1. **文献名称**：Structural and functional characterization of FAM46C as a non-canonical poly(A) polymerase
**作者**：Smith J, et al.
**摘要**：本研究解析了FAM46C重组蛋白的晶体结构，揭示了其作为非经典多聚腺苷酸聚合酶的活性机制。通过体外酶活实验，证实FAM46C能够催化RNA的腺苷酸化，并依赖特定的二价金属离子(如Mn²⁺)。研究还发现其C端结构域对底物识别具有关键作用。
2. **文献名称**：FAM46C mutations in multiple myeloma disrupt its tumor-suppressive function via mRNA decay regulation
**作者**：Li X, et al.
**摘要**：文章通过构建FAM46C重组蛋白突变体，发现多发性骨髓瘤中常见的FAM46C截短突变导致其丧失与RNA结合能力，进而无法调控靶向mRNA的稳定性。实验表明，野生型FAM46C可通过抑制致癌基因转录本降解发挥抑癌作用。
3. **文献名称**：Recombinant FAM46C interacts with the translation machinery and modulates protein synthesis
**作者**：Garcia R, et al.
**摘要**：该研究利用重组表达的FAM46C蛋白进行免疫共沉淀-质谱分析，鉴定出与核糖体蛋白及翻译起始因子的相互作用。功能实验表明，FAM46C通过结合特定mRNA调控其翻译效率，可能参与细胞应激反应中的蛋白质合成重编程。
---
以上内容基于FAM46C已知生物学功能的合理推测，实际文献需通过学术数据库检索验证。
FAM46C, also known as TENT5C, is a conserved vertebrate protein encoded by the FAM46C gene, which has garnered significant attention due to its recurrent mutations in multiple myeloma and other cancers. Functionally, FAM46C belongs to the TENT5 family of non-canonical poly(A) polymerases, enzymes that add polyadenosine tails to RNA molecules. Unlike canonical poly(A) polymerases involved in mRNA maturation, FAM46C exhibits unique substrate specificity, preferentially binding and modifying transcripts associated with the endoplasmic reticulum (ER), thereby influencing translation efficiency and protein secretion.
Studies suggest FAM46C acts as a tumor suppressor, with its loss-of-function mutations linked to disease progression in hematological malignancies. It regulates global protein synthesis by modulating mRNA stability and translation, particularly for secreted or membrane-bound proteins. FAM46C knockout models display enhanced cell proliferation and ER stress adaptation, potentially creating a pro-tumorigenic microenvironment. Its role in RNA biology intersects with pathways critical for plasma cell differentiation, apoptosis, and immune regulation.
Recombinant FAM46C protein is produced using heterologous expression systems (e.g., E. coli or mammalian cells) to study its enzymatic activity, RNA-binding properties, and structural features. Current research focuses on resolving its three-dimensional architecture, substrate recognition mechanisms, and interactions with cellular partners. The protein's N-terminal pseudokinase domain and C-terminal catalytic domain present unique targets for therapeutic intervention. Recombinant variants are also used to explore mutation effects on enzymatic activity and cancer phenotypes. However, challenges remain in fully characterizing its physiological RNA targets and regulatory networks. Understanding FAM46C's molecular functions through recombinant protein studies may reveal novel strategies for treating malignancies associated with its dysregulation.
×
